Bavarian Nordic Making All Efforts To Stretch Capacity To Boost Monkeypox Vaccine Supplies

Bavarian Nordic A/S BVNRY said it was making "every effort" to meet the high demand for its monkeypox vaccine worldwide as it kept its business outlook for the year.
The Danish biotech's CEO said the outbreak was "unprecedented" in its first-half results.
Bavarian is the only producer of a vaccine approved against monkeypox. Still, the jab is in short supply, and several countries are stretching out the available doses to make the most of existing supplies, with unknown outcomes.
According to Financial Times, the U.K. has nearly run out of supplies and will not get any more until late September. Health authorities in the U.K., Europe, and the U.S. have backed "fractional dosing" to stretch out supplies.
"We are making every effort to meet the initial worldwide demand for our monkeypox vaccine and are working diligently to further expand our manufacturing capacity through additional scale-up activities and partnerships," CEO Paul Chaplin said.
Related: Bavarian Nordic Recruits US Firm For Packaging Services For Its Monkeypox Vaccine.
He added, "despite our heavy R&D investments, the strong sales performance in all parts of our business during the first six months, together with our projections for the remainder of the year, means that we are now nearing a break-even result for 2022, and we see a robust business for the monkeypox vaccine building up beyond 2022."
The company reported 1H sales of DKK 857 million, with Q2 sales of DKK 537 million.
EBITDA loss in the first half year was DKK (212) million.
The company upgraded its guidance six times since March, maintaining the latest sales guidance of DKK 2.7-2.9 billion and an EBITDA loss of DKK (300)- (100) million.
Price Action: BVNRY shares closed at $15.49 on Tuesday.

Market News and Data brought to you by Benzinga APIs

Comments

Earnings Calendar

Never Miss Important Catalysts

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga